Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel W Lin

Showing results (231-240 of 287) with videos related to

Pageof 29
Sort By:
European Urology Oncology|March 24, 2024
Three- and Seven-month Prostate-specific Antigen Levels as Prognostic Markers for Overall Survival in Metastatic Hormone-sensitive Prostate Cancer: Results from SWOG S1216, a Phase 3 Randomized Trial of Androgen Deprivation Plus Orteronel or BicalutamideMamta Parikh, Catherine Tangen, Maha H A Hussain, et al.
JAMA|May 30, 2024
Long-Term Outcomes in Patients Using Protocol-Directed Active Surveillance for Prostate CancerLisa F Newcomb, Jeannette M Schenk, Yingye Zheng, et al.
Cancer Medicine|April 25, 2022
Germline mutations in penetrant cancer predisposition genes are rare in men with prostate cancer selecting active surveillanceLauren Brady, Lisa F Newcomb, Kehao Zhu, et al.
Clinical Chemistry|November 21, 2007
SELDI-TOF MS whole serum proteomic profiling with IMAC surface does not reliably detect prostate cancerDale McLerran, William E Grizzle, Ziding Feng, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|May 14, 2016
Analytic validation of a clinical-grade PTEN immunohistochemistry assay in prostate cancer by comparison with PTEN FISHTamara L Lotan, Wei Wei, Olga Ludkovski, et al.
The Prostate|June 22, 2016
Loss of Expression of AZGP1 Is Associated With Worse Clinical Outcomes in a Multi-Institutional Radical Prostatectomy CohortJames D Brooks, Wei Wei, Jonathan R Pollack, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 4, 2008
Phase III prevention trial of fenretinide in patients with resected non-muscle-invasive bladder cancerAnita L Sabichi, Seth P Lerner, E Neely Atkinson, et al.
Scientific Reports|January 4, 2024
High expression of Trop2 is associated with aggressive localized prostate cancer and is a candidate urinary biomarkerShiqin Liu, Sarah J Hawley, Christian A Kunder, et al.
Prostate Cancer and Prostatic Diseases|November 14, 2019
Prospective study to define the clinical utility and benefit of Decipher testing in men following prostatectomyJoseph Marascio, Daniel E Spratt, Jingbin Zhang, et al.
Practical Radiation Oncology|November 26, 2019
Clinical Utility of a Genomic Classifier in Men Undergoing Radical Prostatectomy: The PRO-IMPACT TrialJohn L Gore, Marguerite du Plessis, Jingbin Zhang, et al.
Pageof 29

Showing results (231-240 of 287) with videos related to

Sort By:
Pageof 29
European Urology Oncology|March 24, 2024
Three- and Seven-month Prostate-specific Antigen Levels as Prognostic Markers for Overall Survival in Metastatic Hormone-sensitive Prostate Cancer: Results from SWOG S1216, a Phase 3 Randomized Trial of Androgen Deprivation Plus Orteronel or BicalutamideMamta Parikh, Catherine Tangen, Maha H A Hussain, et al.
JAMA|May 30, 2024
Long-Term Outcomes in Patients Using Protocol-Directed Active Surveillance for Prostate CancerLisa F Newcomb, Jeannette M Schenk, Yingye Zheng, et al.
Cancer Medicine|April 25, 2022
Germline mutations in penetrant cancer predisposition genes are rare in men with prostate cancer selecting active surveillanceLauren Brady, Lisa F Newcomb, Kehao Zhu, et al.
Clinical Chemistry|November 21, 2007
SELDI-TOF MS whole serum proteomic profiling with IMAC surface does not reliably detect prostate cancerDale McLerran, William E Grizzle, Ziding Feng, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|May 14, 2016
Analytic validation of a clinical-grade PTEN immunohistochemistry assay in prostate cancer by comparison with PTEN FISHTamara L Lotan, Wei Wei, Olga Ludkovski, et al.
The Prostate|June 22, 2016
Loss of Expression of AZGP1 Is Associated With Worse Clinical Outcomes in a Multi-Institutional Radical Prostatectomy CohortJames D Brooks, Wei Wei, Jonathan R Pollack, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 4, 2008
Phase III prevention trial of fenretinide in patients with resected non-muscle-invasive bladder cancerAnita L Sabichi, Seth P Lerner, E Neely Atkinson, et al.
Scientific Reports|January 4, 2024
High expression of Trop2 is associated with aggressive localized prostate cancer and is a candidate urinary biomarkerShiqin Liu, Sarah J Hawley, Christian A Kunder, et al.
Prostate Cancer and Prostatic Diseases|November 14, 2019
Prospective study to define the clinical utility and benefit of Decipher testing in men following prostatectomyJoseph Marascio, Daniel E Spratt, Jingbin Zhang, et al.
Practical Radiation Oncology|November 26, 2019
Clinical Utility of a Genomic Classifier in Men Undergoing Radical Prostatectomy: The PRO-IMPACT TrialJohn L Gore, Marguerite du Plessis, Jingbin Zhang, et al.
Pageof 29